Evaluation and development of the novel measurement method for multiple myeloma

Evaluation and development of the novel measurement method for multiple myeloma - Novel measurement method for multiple myeloma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022763

Enrollment

Registered

2016-06-16

Start date

2015-07-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Interventions

Classification of myeloma cells and the detection of minimal residual disease by analysis of gene amplication of 1q21, 8 color flowcytometry

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Newly and previously diagnosed multiple myeloma patients with written informed consent

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Correlation of 1q21 amplification and minimal residual disease with clinical response and other laboratory parameter	—

Countries

Japan

Contacts

Public ContactShotaro Hagiwara

National Center for Global Health and Medicine Hematology

shagiwar@hosp.ncgm.go.jp+81-3-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026